The Vif protein of human immunodeficiency virus type 1 (HIV-1): Enigmas and solutions

被引:8
作者
Baraz, L [1 ]
Kotler, M [1 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pathol, IL-91120 Jerusalem, Israel
关键词
HIV-1; Vif; protease; peptide-mapping; protease inhibitors; drug resistance; cellular anti HIV-1 factor;
D O I
10.2174/0929867043456124
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HIV-1 and other complex retroviruses express six auxiliary genes in addition to the canonical retroviral genes, gag, pol and env. Vif (virion infectivity factor) protein is absolutely essential for productive HIV-1 infection of peripheral blood lymphocytes and macrophages, the two major HIV-1 target cells in vivo. However, Vif is not required for production of infectious particles in several human cell lines. In spite of the prominent phenotype of Vif mutations, the mechanism of its action remains unknown. During the last decade several models were suggested to explain the mechanism of Vif activity. One view holds that Vif is active in virions after budding or after entry into target cells during the early stages of HIV-1 replications. The second view places the action of Vif at the late stage of HIV-1 replication in virus producing cells, which affects the production of infectious virus. According to this view, Vif either compensates the cell factor required for production of infectious virus, or alternatively, it neutralizes a cell factor, which prevents the production of infectious particles in these cells. This review is addressed to summarize the models envisioned to explain Vif activities. The findings described here, that Vif interacts with viral and cellular components, elaborates the importance of Vif as a novel target for developing anti HIV-1 drugs.
引用
收藏
页码:221 / 231
页数:11
相关论文
共 103 条
[1]   Pseudotyping human immunodeficiency virus type 1 by vesicular stomatitis virus G protein does not reduce the cell-dependent requirement of Vif for optimal infectivity: functional difference between Vif and Nef [J].
Akari, H ;
Uchiyama, T ;
Fukumori, T ;
Iida, S ;
Koyama, AH ;
Adachi, A .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :2945-2949
[2]   Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice [J].
Aldrovandi, GM ;
Zack, JA .
JOURNAL OF VIROLOGY, 1996, 70 (03) :1505-1511
[4]   SYNTHETIC INTERFACE PEPTIDES ALTER DIMERIC ASSEMBLY OF THE HIV-1 AND HIV-2 PROTEASES [J].
BABE, LM ;
ROSE, J ;
CRAIK, CS .
PROTEIN SCIENCE, 1992, 1 (10) :1244-1253
[5]   Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production [J].
Baraz, L ;
Friedler, A ;
Blumenzweig, I ;
Nussinuv, O ;
Chen, N ;
Steinitz, M ;
Gilon, C ;
Kotler, M .
FEBS LETTERS, 1998, 441 (03) :419-426
[6]   Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region [J].
Baraz, L ;
Hutoran, M ;
Blumenzweig, I ;
Katzenellenbogen, M ;
Friedler, A ;
Gilon, C ;
Steinitz, M ;
Kotler, M .
JOURNAL OF GENERAL VIROLOGY, 2002, 83 :2225-2230
[7]   Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors:: co-encapsidation and interference with viral protease-mediated Gag processing [J].
Bardy, M ;
Gay, B ;
Pébernard, S ;
Chazal, N ;
Courcoul, M ;
Vigne, R ;
Decroly, E ;
Boulanger, P .
JOURNAL OF GENERAL VIROLOGY, 2001, 82 :2719-2733
[8]   Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations [J].
Bess, JW ;
Gorelick, RJ ;
Bosche, WJ ;
Henderson, LE ;
Arthur, LO .
VIROLOGY, 1997, 230 (01) :134-144
[9]   TRANSCOMPLEMENTATION OF VIF- HIV-1 MUTANTS IN CEM CELLS SUGGESTS THAT VIF AFFECTS LATE STEPS OF THE VIRAL LIFE-CYCLE [J].
BLANC, D ;
PATIENCE, C ;
SCHULZ, TF ;
WEISS, R ;
SPIRE, B .
VIROLOGY, 1993, 193 (01) :186-192
[10]   Plasticity of cell fate: Insights from heterokaryons [J].
Blau, HM ;
Blakely, BT .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 1999, 10 (03) :267-272